All In Biotech

Drug Trial Radar · NCT07581210

Efficacy and Safety of QD202 in Participants With Acute Ischemic Stroke Undergoing Thrombolysis Excluding Endovascular Thrombectomy

A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety, Pharmacokinetic Profile, and Efficacy of QD202 Injection in Patients With Acute Ischemic Stroke Undergoing Thrombolysis

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 14, 2025

Primary completion

Aug 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
May 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blinded, placebo-controlled study investigating the safety and efficacy of QD202 injection in patients with acute ischemic stroke undergoing thrombolysis excluding endovascular thrombectomy. Up to 120 male and female patients with acute ischemic stroke undergoing thrombolysis excluding endovascular thrombectomy will be dosed with QD202 injection or placebo as a 60 minute intravenous infusion after completion of the thrombolysis procedure on Day 1-5 of the study period. Subjects will undergo interim procedures at Day 7 or the day of discharge, Day 30, and end-of-study procedures on Day 90.

Conditions

  • Acute Ischemic Stroke

Interventions

  • QD202Drug

    QD202 is a 19 amino acid peptide that consists of a 8 amino acid active domain and an 11 amino acid domain that enables the peptide to cross the blood-brain barrier.

  • PlaceboDrug

    The placebo matches the investigational drug in appearance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and ToleranceTime frame: Through study completion, an average of 90 days

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Meizhou People's Hospital

    Meizhou, Guangdong, China · Recruiting

  • Luoyang Central Hospital

    Luoyang, Henan, China · Recruiting

  • Nanshi Hospital of Nanyang

    Nanyang, Henan, China · Recruiting

  • Jilin Province People's Hospital

    Changchun, Jilin, China · Recruiting

  • Meihe Hospital the First Hospital of Jilin University

    Meihekou, Jilin, China · Recruiting

  • Benxi Central Hospital

    Benxi, Liaoning, China · Recruiting

  • General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group

    Fuxin, Liaoning, China · Recruiting

  • Central Hospital Affiliated to Shenyang Medical College

    Shengyang, Liaoning, China · Recruiting

  • General Hospital of Northern Theater Command

    Shenyang, Liaoning, China · Recruiting

  • Linyi People's Hospital

    Linyi, Shandong, China · Recruiting

  • Weifang People's Hospital

    Weifang, Shandong, China · Recruiting

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Linfen Central Hospital

    Linfen, Shanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.